Anemia at Admission and Clinical Outcomes in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Document Type : Original Article

Authors

Department of Cardiology, Tanta Faculty of Medicine, Egypt.

Abstract

Background: Anemia is common in ST-elevation myocardial infarction (STEMI) patients. The influence of anemia on the prognosis of STEMI patients remains unclear. Robust data are lacking regarding the outcome of patients with moderate-to-severe anemia who present with STEMI and who are treated via primary percutaneous coronary intervention (PCI). This study aimed to evaluate the effects of chronic anemia on major adverse cardiovascular and cerebral events (MACCE) in patients with STEMI undergoing primary PCI.
 
Methods: The present study recruited 330 consecutive STEMI patients who underwent primary PCI from November 2017 through October 2019 at our cardiology department. The study population was divided into 2 groups according to the hemoglobin level after primary PCI. The patients’ baseline clinical characteristics and relationships between hemoglobin levels and the incidence of MACCE during a 1-year follow-up were recorded.
 
Results: Patients with a hemoglobin level of less than 11 g/dL were elderly, had a lower body mass index, a higher incidence rate of diabetes, a higher Killip class at presentation, and a higher incidence rate of MACCE. Anemia at admission was an independent predictor of MACCE during hospitalization and on post-primary PCI follow-ups at 30 days, 6 months, and 1 year after PCI (P=0.034, 0.028, 0.0032, and 0.0042, respectively).
 
Conclusions: Age, hypertension, and diabetes in STEMI patients with moderate-to-severe anemia were associated with an increased incidence rate of MACCE. Moderate-to-severe anemia at admission was an independent predictor of MACCE during hospitalization and on post-primary PCI follow-ups at 30 days, 6 months, and 1 year.  (Iranian Heart Journal 2021; 22(2): 58-67)

Keywords

References

  1. Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569 –2619.
  2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, Baumbach A, Bugiardini R, Coman IM, Delgado V, Fitzsimons D, Gaemperli O, Gershlick AH, Gielen S, Harjola VP, Katus HA, Knuuti J, Kolh P, Leclercq C, Lip GYH, Morais J, Neskovic AN, Neumann FJ, Niessner A, Piepoli MF, Richter DJ, Shlyakhto E, Simpson IA, Steg PG, Terkelsen CJ, Thygesen K, Windecker S, Zamorano JL, Zeymer U. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39(2):119–77.
  3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.
  4. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042–2049.
  5.  Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–533.
  6.  Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase:clinical findings through hospital discharge. Circulation.1987; 76:142–154.
  7. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230–1236.
  8. Most AS, Ruocco NA Jr, Gewirtz H. Effect of a reduction in blood viscosity on maximal myocardial oxygen delivery distal to a moderate coronary stenosis. Circulation. 1986; 74:1085–1092.
  9. Levy PS, Quigley RL, Gould SA. Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. J Trauma. 1996; 41:416–423.
  10. Cappellini MD and Motta I. Anemia in clinical practice – definition and classification: does hemoglobin change with aging? Semin Hematol 2015; 52: 261–269.
  11. World Health Organization. (‎2011)‎. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization. https://apps.who.int/iris/handle/10665/85839
  12. Moghaddam N, Wong GC, Cairns JA, et al. Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2018;11(12):e007175. doi:10.1161/CIRCINTERVENTIONS.118.007175
  13. Y.Liu, Y.Yang, J.Zhu, H.Tan, Y.Liang, and J.Li, “Anaemia and Prognosisin Acute Coronary Syndromes: ASystematic Review and Meta-Analysis,” Journal of International Medical Research, vol.40, no.1, pp.43–55, 2012.
  14. Greenberg G, Assali A, Vaknin-Assa H, et al. Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. Am J Cardiol 2010; 105:435-40.
  15. Liu CW, Liao PC, Chen KC, et al. Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients. Acta Cardiol Sin. 2016; 32(6):656-666. doi:10.6515/acs20160106a
  16. Tsujita K, Nikolsky E, Lansky AJ, et al. Impact of anemia on clinical outcomes of patients with ST-Segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol 2010; 105: 1385-94.
  17. RathodKS, JonesDA, RathodVS, etal. Prognosticimpact of anaemia on patients with ST-elevation myocardial infarction treated by primary PCI. Coron Artery Dis 2014;25:52-9
  18. . J. Bassand, “Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm,” European Heart Journal, vol.28, no.11, pp. 1273-1274, 2007.
  19. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.Am J Cardiovasc Drugs 2013; 13: 435-42.
  20. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.Am J Cardiovasc Drugs 2013; 13:435-42.
  21. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3:408-13.
  22. Bernat I, Horak D, Stasek J, et al. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial the STEMI-RADIAL trial. J Am Coll Cardiol 2014; 63:964-72.
Iranian Heart Journal
Volume 22, Issue 2
April 2021
Pages 58-67

Files

Share

How to cite

Statistics